Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer’s product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon.

You may also be interested in...



FDA Clears 31 New Molecular Entities In 2004, Up 10 From Previous Year

NME rebound in 2004? Final count is 31 versus 21 in 2003 – however, 2004 tally includes several atypical new molecular entities. Top 10 pharma companies hold small share of the total, with no companies clearing more than two NMEs during the year. Over 20% of the approvals came in the last two weeks of December

FDA Clears 31 New Molecular Entities In 2004, Up 10 From Previous Year

NME rebound in 2004? Final count is 31 versus 21 in 2003 – however, 2004 tally includes several atypical new molecular entities. Top 10 pharma companies hold small share of the total, with no companies clearing more than two NMEs during the year. Over 20% of the approvals came in the last two weeks of December

FDA Has 19 Applications Remaining With User Fees In 2004: 7 NMEs, 1 BLA

With seven first-cycle new molecular entities with user fee deadlines in November and December, FDA could surpass the total number of new molecular entities approved in 2003.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS002453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel